Sarecycline Explained

Pronounce:	sar"e sye' kleen
Tradename:	Seysara
Dailymedid:	Sarecycline
Routes Of Administration:	By mouth
Atc Prefix:	J01
Atc Suffix:	AA14
Legal Us:	Rx-only
Legal Us Comment:	^[1]
Index2 Label:	as HCl
Cas Number:	1035654-66-0
Pubchem:	54681908
Pubchem2:	71296095
Chemspiderid:	28540486
Unii:	94O110CX2E
Drugbank:	DB12035
Drugbank2:	DBSALT002125
Kegg:	D10666
Kegg2:	D10667
Chembl:	2364632
Pdb Ligand:	V7A
Synonyms:	P-005672
Iupac Name:	(4S,4aS,5aR,12aR)-4-(Dimethylamino)-1,10,11,12a-tetrahydroxy-7-methoxy(methyl)aminomethyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
C:	24
H:	29
N:	3
O:	8
Smiles:	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC

Sarecycline, sold under the brand name Seysara, is a narrow-spectrum tetracycline-derived antibiotic medication.^{[2] [3]} It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest).^[4] Efficacy was assessed in a total of 2002 subjects 9 years of age and older. Unlike other tetracycline-class antibiotics, sarecycline has a long C7 moiety that extends into and directly interact with the bacterial messenger RNA (mRNA).^[5] The spectrum of activity is limited to clinically relevant Gram-positive bacteria, mainly Cutibacterium acnes, with little or no activity against Gram-negative bacterial microflora commonly found in the human gastrointestinal tract.^[6]

Medical uses

Sarecycline, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Notes and References

1. Web site: Seysara- sarecycline hydrochloride tablet, coated . DailyMed . U.S. National Library of Medicine . 1 August 2021 . 31 March 2023.
2. Zhanel G, Critchley I, Lin LY, Alvandi N . Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris . Antimicrobial Agents and Chemotherapy . 63 . 1 . January 2019 . 30397052 . 6325184 . 10.1128/AAC.01297-18 .
3. Web site: PubChem . U.S. National Library of Medicine . Sarecycline. 2020-09-05 .
4. Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, Cook-Bolden FE, Dhawan SS, Forsha D, Gold MH, Guenthner S, Kempers SE, Kircik LH, Parish JL, Rendon MI, Rich P, Stein-Gold L, Tyring SK, Weiss RA, Nasir A, Schmitz C, Boodhoo TI, Kaoukhov A, Berk DR . 6 . Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind Clinical Trials . Journal of Drugs in Dermatology . 17 . 9 . 987–996 . September 2018 . 30235387 .
5. Batool Z, Lomakin IB, Polikanov YS, Bunick CG . Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome . Proceedings of the National Academy of Sciences of the United States of America . 117 . 34 . 20530–20537 . August 2020 . 32817463 . 7456112 . 10.1073/pnas.2008671117 . free . 2020PNAS..11720530B .
6. Zhanel G, Critchley I, Lin LY, Alvandi N . Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris . Antimicrobial Agents and Chemotherapy . 63 . 1 . January 2019 . 30397052 . 6325184 . 10.1128/AAC.01297-18 . free .